Loading
Exact Sciences' multi-cancer blood test, sold since 2025 as a lab test that has not been through FDA approval.
Cancerguard launched in September 2025 as a laboratory-developed test priced for self-pay, built on the multi-biomarker approach validated in the Falcon Registry and DETECT-A studies (the latter, with Johns Hopkins, was the first prospective interventional study of a multi-cancer blood test). Unlike Galleri it does not predict where a cancer is, so a positive result triggers whole-body imaging. As an LDT it is regulated through CLIA rather than the FDA, a status confirmed when the FDA's 2024 LDT rule was vacated in 2025. No randomised trial has yet shown that a multi-cancer blood test reduces deaths.
Plasma assay combining cell-free DNA methylation and protein biomarkers across multiple classes, reporting a cancer signal without a tissue-of-origin call, followed by imaging work-up.
1.Cancerguard slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Cancerguard" OR ABSTRACT:"Cancerguard") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cancerguard, not a curated reading list.
Shares Exact Sciences (Abbott), Shield, Positive predictive value (PPV), Screening and the tag test.
Shares Exact Sciences (Abbott), Shield, Screening, DNA methylation profiling and the tag test.
Shares Shield, Screening, DNA methylation profiling, Liquid biopsy (ctDNA) and the tag test.
Shares Exact Sciences (Abbott), Liquid biopsy (ctDNA) and the tag test.
Shares DNA methylation profiling, Liquid biopsy (ctDNA) and the tag test.
Shares Liquid biopsy (ctDNA) and the tag test.
Shares Liquid biopsy (ctDNA) and the tag test.
Shares Liquid biopsy (ctDNA) and the tag test.